Fundz

Iktos Raises € 15.5M Series A Round To Expand Its Artificial Intelligence-Based Drug Discovery Technologies And Solutions

PRIVATEMar 09, 2023

Amount Raised

€15.5 Million

Round Type

Series A

ParisInformation TechnologyBiotechnologySoftwareArtificial IntelligenceMachine Learning

Investors

Omnes CapitalDebiopharm Innovation FundM Ventures

Description

Iktos, a company specializing in artificial intelligence for new drug discovery, today announces the closing of a € 15.5m Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital.

Quick answer

Iktos raised €15.5 Million in a Series A round, dated March 9, 2023. Investors: Omnes Capital, Debiopharm Innovation Fund and M Ventures. Iktos is based in Paris, Ile-de-France, France.

How much did Iktos raise?
Iktos raised €15.5 Million in a Series A round on March 9, 2023.
Who invested in Iktos?
Omnes Capital, Debiopharm Innovation Fund and M Ventures are named as investors in this round.
What does Iktos do?
Iktos is a French start-up specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically to medicinal chemistry and new drug design.
Where is Iktos based and how big is it?
Iktos is based in Paris, Ile-de-France, France.
Who are the decision-makers at Iktos?
Fundz holds 1 contact at Iktos. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology and Software around the same time

Companies in the same sectors as Iktos that raised within 45 days of this round, from Fundz verified event records.

  • COMPL-AI raised $1.7M (Seed) on April 20, 2023.
  • Robust.AI raised $20M (Funding Round) on April 20, 2023.
  • Groundlight raised $10M (Seed) on April 19, 2023.
  • Loopin raised $1.9M (Seed) on April 17, 2023.
  • Distyl AI raised $7M (Funding Round) on April 13, 2023.
  • Patri raised $2.4M (Seed) on April 11, 2023.

Who to call at Iktos, and when

A new round usually means Iktos is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Iktos raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Iktos, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Iktos. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Iktos

Location

Paris, Ile-de-France, France

About

Iktos is a French start-up specializing in the development of artificial intelligence (AI) solutions applied to chemical research, more specifically to medicinal chemistry and new drug design. Iktos develops a proprietary and innovative solution based on generative deep learning models, which allows, from existing data, to design optimized molecules in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology platform enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, MakyaTM. Iktos also develops SpayaTM, a synthesis planning software based on Iktos' proprietary AI technology for retrosynthesis. Iktos has already validated its technology through more than 50 collaborations with pharmaceutical and biotech companies such as Chiesi Group, Galapagos, Janssen, Merck, Teijin, Ono Pharmaceuticals, Pfizer, Servier, UCB...

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Iktos raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Iktos's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Iktos raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.